Our previous observations also demonstrate that TrkB expression in breast cancer induces metastatic potential by both JAK2/STAT3 and PI3K/AKT activation and induced metastasis of breast cancer mediated suppression of RUNX3 and KEAP1 expression by TrkB. Also, TrkB induced metastatic potential of cancer and suppressed the growth inhibitory activity in response to BMP signaling by preventing BMRRI/BMPRII complex formation. The previous report BMP-2 and BMP4 trigger tumor inhibitory activity in colorectal cancer by upregulation of RUNX3 expression. Although TrkB may regulate tumor inhibitory activity by BMP-induced upregulation of RUNX3, it is not still fully understood how TrkB signaling adjusts to inhibit BMP signaling-mediated tumor suppression.Our findings provide important molecular insights into TrkB-mediated modulation of BMP signaling has remained unknown, and none of the studies still reported a correlation between TrkB and BMP signaling. Our current study surprisingly showed that unique role of TrkB in the regulation of BMP-induced tumor inhibitory activity and BMP-2-induced RUNX3 expression.
Introduction
The bone morphogenetic proteins (BMPs) family, which are consists of over 20 types of BMPs, are one of transforming growth factor-β (TGF-β) superfamily and are multifunctional growth factors with a broad range of regulatory functions, including embryonic development, apoptosis, chemotaxis, proliferation, and cellular differentiation [1] [2] [3] [4] . As TGF-β signaling, secreted BMP-2 signals through a complex of BMP type II (BMPRII) and BMP type I (BMPRIA) receptor on the cell surface leads to activation of SMAD1 and thereby facilitates the nuclear translocation of SMAD1 in association with SMAD4 to regulate specific target gene expression [5] [6] [7] .
Like functions of TGF-β in cancer microenvironments, BMPs and their receptors have implicated an essential role as a dual function, which has a tumor suppressor and promoter of tumor progression in cancer. For example, Gremlin 1 expression, BMP-antagonist, in an analysis of large patient cohorts significantly increased in tumor tissues of breast cancer patients [8] . Also, Gremlin 1 induces tumorigenesis of cancer cells by inhibiting BMP/SMAD signaling and associated poor prognosis of breast cancer patients [9] . Moreover, estrogen treatment increases the reduction of BMPRI [10] . Furthermore, expression of BMPRI or BMPRII exhibited significant loss in patients of poorly differentiated prostate cancer, renal cell carcinoma, urinary bladder cancer [5, 11, 12] and BMPRI expression frequently reduced and associated with poor survival in pancreatic cancer patients and inactivation of BMP signaling induces invasiveness of tumor [6] and BMP-2 induced apoptosis of glioma by induction of BMPRI [13] . However, other studies suggest that BMP signaling engaged in tumorigenesis and metastasis of tumors as tumor promotor. For instance, inhibition of BMP signaling by the antagonist of the BMPRIs (alk2, alk3, and alk6) decreases the growth and eventually promotes cell death in lung cancer cells [14] . Also, loss of BMPRIB associated with poor survival of breast cancer patients and render to the acquirement of drug-resistance [15] . So, it is still not completely clear what is a function of BMP signaling in tumor progression.
The recent studies, including our studies, demonstrated that BDNF and its TrkB receptor crucial role in tumorigenesis and metastasis of cancer and associated with poor survival of various cancer patients. BDNF/TrkB signaling activated in various cancer types, including breast cancer [16] , colon cancer [17] , lung cancer [18] , pancreatic cancer [19] , cutaneous melanoma [20], ovarian cancer [21] , oral squamous cell carcinoma (OSCC). Also, Its expression associated with poor prognosis of melanoma and OSCC patients [22] . Moreover, TrkB inhibition induces suppression of survival of medulloblastoma by induction of apoptosis [23] . Our previous observations also demonstrate that TrkB expression in breast cancer induces metastatic potential by both JAK2/STAT3 and PI3K/AKT activation [24] and induced metastasis of breast cancer mediated suppression of RUNX3 and KEAP1 expression by TrkB [16] . The previous report described BMP signaling have linked to regulation of RUNX3 expression, a tumor suppressor. BMP-2 and BMP4 trigger tumor inhibitory activity in colorectal cancer by upregulation of RUNX3 expression [25] . Although TrkB may regulate tumor inhibitory activity by BMP-induced upregulation of RUNX3, it is not still fully understood how TrkB signaling adjusts to inhibit BMP signaling-mediated tumor suppression.
We show here that TrkB induced metastatic potential of cancer and suppressed the growth inhibitory activity in response to BMP signaling by preventing BMRRI/BMPRII complex formation.
Results

TrkB expression drives inhibition of established BMP signaling
To understand the correlation between TrkB expression and BMP signaling, we examined whether TrkB expression modulates BMP response element (BRE) luciferase activity. The transient transfection of TrkB in RIE-1, HeLa, and NMuMG cells inhibits BRE-luciferase activity relative to that of control (Figures 1A, 1B , and S1A). Thus, TrkB may inhibit BMP signaling for the acquisition of invasion and tumorigenesis of a tumor. To test this hypothesis, we generated RIE-1 and HeLa cells which overexpressed TrkB (Data not shown).
As expected, BMP-2-induced transcriptional activity in RIE-1-TrkB and NMuMG-TrkB cells reduced by TrkB overexpression (Figures 1C and S1B) . In normal RIE-1 and HeLa cells, BMP-2-induced phosphorylation of SMAD1 was readily detectable but increased SMAD1 phosphorylation markedly reduced in RIE-1-and HeLa-TrkB cells relative to RIE-1 and 1D and 1E) . To further understand the function of TrkB on the BMP-2 signaling, we then investigated whether TrkB suppresses BMP-2-induced growth inhibition. RIE-1-TrkB cells were resistant to BMP-2-induced growth inhibition. RIE-1 cells failed to resistant to BMP-2-induced growth inhibition observed in RIE-1-TrkB cells (Figure 1F) .
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These results suggest that TrkB expression inhibits BMP-2-induced growth inhibitory activity.
TrkB promotes the ability of tumorigenicity and Metastasis of RIE-1 Cells
The above results suggest that TrkB expression may enhance the tumorigenic potential of the tumor by BMP-2-mediated growth inhibition. Based on the above findings, we evaluated whether TrkB overexpression leads to the induction of metastatic potential to RIE-1 cells. To metastasize to distant organs, cancer cells have to overcome anoikis during cancer progression [26] . We first examined whether TrkB confers anoikis resistance to achieve invasion and dissemination, which is the hallmark for metastatic cancer. RIE-1-TrkB cells form large aggregates in suspension and promote cell anchorage-independent growth relative to RIE-1 cells (Figure 2A) . In cell migration assay, RIE-1-TrkB cells had markedly increased cell migration, but RIE-1 cells significantly decreased cell migration, indicating that the increased cell migration correlated with the level of TrkB expression ( Figure 2B ). We then investigated whether TrkB expression affected the colony-forming ability of RIE-1 cells.
RIE-1-TrkB cells increase 3 ~ 4 fold higher colony-forming activity relative to RIE-1 cells ( Figure 2C ). Next, we performed an in vitro mammosphere forming assay, which is associated with mammary stem-like traits [27] . Relative to the parental RIE-1 cells, RIE-1-TrkB cells were 2.6 fold enriched in mammosphere-forming cells (Figure 2D) . Also, in wound healing assay, TrkB overexpression in RIE-1 cells significantly increases cell motility compared with that in parental RIE-1 cells (Figure 2E) , indicating that TrkB expression enhances tumor outgrowth. Also, these findings suggest that TrkB accelerates the invasionmetastasis cascade for disseminating to distant organ sites.
Loss of TrkB restore BMP-mediated tumor inhibitory activity
To further substantiate the regulation of BMP signaling in the tumor invasion function of TrkB, we also knocked down the expression of TrkB in MDA-MB-231 and Hs578T cells and found that knockdown of TrkB led to a drastically increases BMP-2-induced BRE transcriptional activity relative to control-shRNA cells (Figures 3A and 3B) . We also observed SMAD1 phosphorylation in MDA-MD-231 TrkB-shRNA cells being increased after BMP-2 stimulation, whereas the treatment of BMP-2 fails to induction of phosphorylation of SMAD1 in MDA-MB-231 control-shRNA cells ( Figure 3C ). We then examined whether TrkB knockdown restored BMP-2-induced growth inhibition. MDA-MB-231 control-shRNA cells were resistant to BMP-2-induced growth inhibition, whereas this resistance to BMP-2-mediated growth inhibition severely compromised in TrkB knockdown cells ( Figure 3D) . These results indicate that TrkB plays a role in suppressing BMP-2mediated growth inhibitory activity for supporting tumor invasion and metastasis.
TrkB directly interacts with BMP type II receptor to inhibits BMP signaling
Our above results suggest that TrkB may suppress BMP-mediated tumor inhibitory activity through the regulation of upstream BMP receptors. To unravel the mechanism of TrkBmediated BMP-2 signaling regulation, we speculated that TrkB might suppress BMP signaling via interacting with BMP receptors. So, we sought to identify proteins that distinctly recognized by TrkB in BMP-2-mediated tumor inhibitory activity. We found TrkB Figure 4E) . Thus, the kinase domain of BMPRII mediates its interaction with TrkB.
The tyrosine kinase activity of TrkB required for inhibition of BMP-2 signaling
We assessed the effects of TrkB kinase inhibitor in BMP-mediated tumor inhibitory activity Figure 5E ). Also, we were intrigued about the K252a effect to inhibition of BMP-2 signaling in RIE-1-TrkB cells because it implies that activation of TrkB by overexpression may be required for suppression of BMP signaling. We, therefore, validated the possibility that TrkB is activated by overexpression via a coimmunoprecipitation experiment. Our results exhibited that RIE-1-TrkB cells indeed was dramatically increased the phosphorylation level of TrkB regardless with or without BDNF treatment relative to RIE-1 cells (Figure S2) .
These results exhibit that TrkB takes action in inhibition of BMP-induced growth inhibitory effect after activation of TrkB.
To more assess the effects of activation of TrkB in BMP-induced transcriptional activity, we generated RIE-1 TrkB KD cells using vectors that expressing kinase-dead mutant of TrkB (K588M). As expected, the BRE-luciferase activity of RIE-1-TrkB or HeLa-TrkB cells drastically inhibits reporter activity, but the expression of TrkB KD in RIE-1 and HeLa cells fail to suppress reporter activity in response to BMP-2 (Figures 6A and 6B) . Also, although TrkB expression reduced the phosphorylation level of SMAD1, the TrkB K588M failed to do so ( Figure 6C) . These results also suggest that the activation of TrkB by overexpression is sufficient for supporting tumor invasion without BDNF through inhibiting BMP-mediated tumor inhibitory activity.
Our attention also is drawn to possible TrkB KD-BMPRII complex formation. TrkB wild type strongly associated with BMPRII, but the interaction between BMPRII and TrkB KD mutant significantly decreased with or without BMP-2 treatment, and the phosphorylation of BMPRII by TrkB KD mutant restored in response to BMP-2 relative to TrkB wild type (Figure 6D ). Because the interaction between BMPRI and BMPRII enhanced by stimulation of BMP-2, we speculated that BMPRII-TrkB complex formation interferes interaction between BMPRI and BMPRII in the presence of BMP-2. The result showed that BMPRII could strongly bind to BMPRI by treatment of BMP-2, but this binding completely abolished in the presence of TrkB. Also, the increased phosphorylation level of BMPRI after treated BMP-2 markedly decreased by TrkB (Figure 6E) . Moreover, the TrkB-mediated depletion of BMPRII-BMPRI interaction rescued by TrkB kinase-dead mutant (Figure 6F) , indicating that activation of TrkB required for tumorigenesis via inhibition of BMP signaling. (CA-ALK3) [25] , indicating that activation of BMP signaling by phosphorylation or expression of BMPRI may be required for the RUNX3-induced inhibition of c-Myc expression. Previously, we showed that TrkB promotes tumorigenesis and metastasis of breast cancer through suppression of RUNX3 expression [28] , and our present result showed that TrkB does not interact with BMPRI ( Figure 4A) . However, it is still not completely clear how TrkB adjusts to suppress RUNX3 expression by inhibiting BMP signaling. We speculate that TrkB may inhibit BMP-induced tumor growth inhibitory activity through the depletion of RUNX3 expression via regulation of BMPRI expression. To unravel to identify the mechanism of TrkB-mediated suppression of RUNX3 expression in BMP signaling, we examined the expression of BMPRI and BMPRII. The level of mRNA and protein expression of BMPRI severely compromised in Hela-TrkB and RIE-1-TrkB cells relative to Hela and RIE-1 cells (Figures 7A, S3A, and S3B) , but TrkB does not affect BMPRII expression ( Figure S3B) . Inhibiting TrkB kinase activity by mutation of the kinase domain of TrkB effectively rescued loss of BMPRI expression by TrkB but does not affect BMPRII expression in both RIE-1-TrkB and RIE-1-TrkB KD cells (Figures 7B and S3D) . Also, knockdown of TrkB in MDA-MB-231 and Hs578T cells induced BMPRI expression ( Figures 7C, 7D, 7E, 7F, and S3C) but not BMPRII (Figures S3E and S3G) . Moreover, we examined the level of BMPRI expression in the lungs of mice carrying MDA-MB-231 control-shRNA or TrkB-shRNA cells. BMPRI expression in the lungs of mice with MDA-MB-231 control-shRNA cells was significantly lower than that of the MDA-MB-231 TrkB-shRNA cells (Figure 7G) . However, BMPRII expression showed no changed (Figure S3G) .
TrkB regulates expression of BMP type I receptor to inhibits BMP signaling
Our above result showed that complex formation between BMPRI and BMPRII significantly suppressed in the presence of TrkB (Figures 6E and 6F) . Under this condition, we observed whether BMPRI induce RUNX3 expression in response to BMP-2. Markedly (Figure 6I) , but RUNX3 expression does not change by transfection of BMPRII (Figure S4B) .
These results suggest that TrkB inhibits expression of RUNX3 by depleting BMPRI expression.
Discussion
We find that TrkB that induce tumorigenesis and metastasis of cancer via induction of the JAK2/STAT3 pathway and PI3K/AKT pathway also governs the conversion to the suppression of BMP-mediated tumor inhibition. Our and another recent study demonstrated that TrkB expression drastically increased in triple-negative breast cancer [16] relative to other subtypes, and BDNF/TrkB plays a critical role in the generation and renewal of CSCs and recurrence of breast cancer after chemotherapy [29] . BDNF expression markedly increased in recurrent TNBCs isolated from patients after chemotherapy and promotes CSC self-renewal by increasing the ALDH1 expression. Moreover, TrkB+ CSCs exclusively overlapped with the ALDH1+ population, and treatment of BDNF in TrkB+/ALDH1+ cells induces KLF4 expression, which is one of stem cell markers. Furthermore, eradicating the [30, 31] . Moreover, Gremlin 1 promotes its stem cell maintenance in glioma and colorectal cancer [32, 33] , and upregulation of Gremlin 1 significantly correlated with induced stem cell markers and poor survival of estrogen receptor (ER)-negative breast cancer patients [8] . These previous results are conspicuously consistent with our present results. Our current study surprisingly showed that complex formation via disruption of AKT-RASSF1 interaction [41] . Another report showed that canonical BMP signaling induces expression of RUNX3 and BMP2/4-induced RUNX3 suppress tumor growth through repression of c-Myc promoter activity via binging RUNXbinding elements in c-Myc promoter [25] . The potential linkage between BMP signaling and RUNX3 in these previous observations now can be accounted for by the mechanism presented in our results. Our previous and present studies surprisingly showed that 
Plasmids and viral production
RIE-1, HeLa, and NMuMG cells were infected with a V5-TrkB using pLenti6.3/V5-TOPO TA Cloning Kit (Invitrogen) to generate TrkB overexpression cells [24] and and the TrkB K588M mutant using previously described [42] was generated by site-directed mutagenesis with Site-Directed Mutagenesis Kit (ThermoFisher Scientific). To generate a stable knockdown of TrkB, small hairpin-expressing vectors were purchased from Sigma-Aldrich (SHCLNG-NM_006180). Production and infection of target cells were previously described [24] and selected with 2 g/ml puromycin and 500 g/ml G418. Plasmid transfections were carried out using Lipofectamine 2000 (Invitrogen) reagent according to the manufacturer's instructions.
Human breast tumor samples
Proteins extracted from human breast normal and tumor samples obtained as previously described [16, 43] .
Antibodies, Western blotting, immunoprecipitation, and immunofluorescence
We performed Western blotting, immunoprecipitation, and immunofluorescence analysis, as previously described [44] . phospho-SMAD1 (ab214423), SMAD1 (ab63356), BMPRI, BMPRI, phosphor-tyrosine, phosphor-serine, and TrkB were from Abcam. Flag and β-actin were from Sigma-Aldrich; V5 was from Invitrogen; HA, Myc, and GFP were from Santa Cruz Biotechnology.
Invasion, anoikis, wound healing, anchorage-independent cell growth, and mammosphere assays
All the assays performed as previously described [24, 45, 46] . For anchorage-independent cell growth and soft agar assays, 1  10 3 cells/well seeded into 6 well cell culture plates. For the wound healing assay, 1  10 6 cells/well seeded into 6 well cell culture plates. For the invasion assay, 1  10 4 cells seeded into 24-well BD Matrigel invasion chambers with 8 m pores (Corning, 62405-744). For anoikis assay, RIE-1 and RIE-1-TrkB cells were seeded into an Ultra Low Cluster plate (Corning) at 1 × 10 5 cells per well in a six-well plate and photographed at 7days. For mammosphere assay, 1  10 3 cells/well seeded into 96-well ultralow adhesion plates in DMEM medium.
Luciferase reporter assay
3  10 4 cells were transfected BRE-Luciferase reporter plasmid using Lipofectamine 2000 (Invitrogen). The cell lysates collected 48 hr after transfection, and the luciferase activities were measured using the Enhanced Luciferase Assay Kit (BD Biosciences).
RNA preparation and RT-PCR analysis
Total RNA was isolated using RNeasy Mini Kits (Qiagen), and RT-PCR analysis was performed using a One-Step RT-PCR kit (Qiagen) according to the manufacturer's instructions.
For quantitative RT-PCR, reverse transcription performed with the Superscript Ⅳ First-strand synthesis system (Invitrogen) and amplification performed with SYBR Green Mix I (Roche), and All PCR analyses were conducted in triplicate using the 7900HT Fast Real-Time PCR System (Applied Biosystems). The primer sequences used to amplify the investigated genes listed in Supplementary Table 1 .
Statistical analysis.
Data expressed as the means  SEM. Statistical analyses of the data conducted via the Student's t-test (two-tailed). Differences were considered statistically significant at P < 0.001. 
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